There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines Inc (FIXX) and Sesen Bio Inc (SESN) with bullish sentiments.
Homology Medicines Inc (FIXX)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Homology Medicines Inc today and set a price target of $36. The company’s shares closed yesterday at $19.19.
Chattopadhyay wrote:
“Our $36 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF, which is based on: beta of 1.02, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.6%, and tax rate of 15% beginning in FY 2028. Three programs contribute to 100% of our target, including: (1) gene therapy for adult patients with classic PKU, HMI-102 represents 66%; (2) HMI-103, a genome editing program for pediatric PKU contributes about 23%; and (3) HMI-202, an IV gene therapy construct for a one-and-done option for late onset infantile metachromatic leukodystrophy forms the remainder.”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.8% and a 41.5% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Voyager Therapeutics Inc.
Homology Medicines Inc has an analyst consensus of Strong Buy, with a price target consensus of $32.50.
See today’s analyst top recommended stocks >>
Sesen Bio Inc (SESN)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright upgraded Sesen Bio Inc to Buy, with a price target of $3. The company’s shares closed yesterday at $1.90.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -12.1% and a 29.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Sesen Bio Inc is a Moderate Buy with an average price target of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
